<p>Retinal Vein Occlusion (RVO), the second most common sight-threatening retinal vascular disorder after diabetic retinopathy, occurs when retinal veins become blocked, often due to atherosclerosis and blood clots. This blockage increases pressure, leading to hemorrhage, fluid leakage, and macular edema. RVO is categorized into Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO), with risk factors including hypertension, diabetes, stroke, and age, particularly in those over 65. As the geriatric population grows, the prevalence of RVO is expected to rise.</p>
<p>&nbsp;</p>
<p>Macular edema is the primary complication, causing significant vision loss in CRVO and BRVO. Diagnosis involves optical coherence tomography (OCT), fluorescein angiography (FA), and sometimes OCT angiography (OCTA) for assessing capillary perfusion. Fundus autofluorescence can also help identify recent-onset CRVO. Treatments focus on reducing macular edema and managing intraocular neovascularization, though challenges remain in effectively treating advanced cases.</p>
<h2><strong>Retinal Vein Occlusion Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Retinal Vein Occlusion in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total prevalent cases&nbsp;</li>
<li>Total diagnosed prevalent cases&nbsp;</li>
<li>Gender-specific diagnosed prevalent cases</li>
<li>Age-specific diagnosed prevalent cases&nbsp;</li>
<li>Type-specific diagnosed prevalent cases&nbsp;</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/retinal-vein-occlusion-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Retinal Vein Occlusion Epidemiology</strong></span></a></h2>
<ul>
<li>The total prevalent cases of Retinal Vein Occlusion in the 7MM were approximately 2.7 million in 2022.</li>
<li>The US accounted for ~57% of the total prevalent cases of Retinal Vein Occlusion, with ~1.5 million cases in 2022.</li>
<li>EU4 and the UK together accounted for ~30% of the total prevalent cases of Retinal Vein Occlusion, with ~814,000 cases in 2022.</li>
<li>Japan accounted for ~13% of the total prevalent cases of Retinal Vein Occlusion, with ~353,000 cases in 2022.</li>
<li>The diagnosed prevalent cases of Retinal Vein Occlusion in the US were ~935,343 in 2022.</li>
<li>EU4 and the UK accounted for ~408,086 diagnosed prevalent cases of Retinal Vein Occlusion in 2022.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/retinal-vein-occlusion-market"><span style="text-decoration: underline;"><strong>Retinal Vein Occlusion Market</strong></span></a></h2>
<p>The total Retinal Vein Occlusion market size in the 7MM was approximately USD 2,297.5 million in 2022.</p>
<h2>Retinal Vein Occlusion Market Drivers</h2>
<ul>
<li>Rising Prevalence: Increasing cases due to an aging population and higher awareness of eye disorders.</li>
<li>Advancements in Treatments: New therapies like VABYSMO and emerging drugs such as KSI-301 offer improved treatment options with better dosing and potential for vision restoration.</li>
<li>Better Diagnosis: Technological advancements are enabling earlier detection and more effective management.</li>
<li>Lifestyle Factors: Rising diabetes and other risk factors contribute to more RVO cases.</li>
</ul>
<h2>Retinal Vein Occlusion Market Barriers</h2>
<ul>
<li>High Costs: Expensive treatments like EYLEA and LUCENTIS limit patient access.</li>
<li>Side Effects: Adverse effects from treatments, including injection site reactions, can affect patient compliance.</li>
<li>Biosimilars: The entry of biosimilars like BYOOVIZ is increasing competition and limiting market share for branded therapies.</li>
<li>Limited Access: Availability of specialized care in rural or underserved areas remains a barrier to effective treatment.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight"><span style="text-decoration: underline;"><strong>Retinal Vein Occlusion Emerging Drugs</strong></span></a></h2>
<p>The emerging drugs of the Retinal Vein Occlusion market are</p>
<ul>
<li>VABYSMO (faricimab)</li>
</ul>
<p>And others.</p>
<h2><strong>Retinal Vein Occlusion Key Players</strong></h2>
<p>The key players in the Retinal Vein Occlusion market are</p>
<ul>
<li>Roche</li>
</ul>
<p>And others.</p>

Retinal Vein Occlusion Market 

Retinal Vein Occlusion Market Infographic

Retinal Vein Occlusion Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.